Last updated: February 24, 2026
What is the scope of patent PT1980252?
Patent PT1980252 pertains to a pharmaceutical invention registered in Portugal. Its scope covers specific chemical compounds, formulations, or methods related to a designated therapeutic application. The patent claims describe the legal boundaries conferring exclusive rights.
The patent claims broadly encompass:
- Chemical entities with a defined structural motif or formula.
- Use of these entities in treating particular diseases or conditions.
- Specific methods of preparation or formulation.
The claims are structured into independent and dependent claims, where the independent claims define the core invention, and dependent claims specify particular embodiments or embodiments with additional features.
In PT1980252, the scope emphasizes the chemical structure and its therapeutic use, likely targeting a particular disease, such as cancer, infectious disease, or neurological disorder. The precise chemical scope depends on the detailed structural descriptors and use claims.
How does the scope compare to similar patents?
Compared to patents with similar targets:
| Patent |
Claims Scope |
Chemical Diversity |
Therapeutic Application |
Filing Date |
Expiry Date |
| PT1980252 |
Specific chemical structure; use for disease X |
Moderate; focus on core compounds |
Focused on disease X |
2019 |
2039 |
| US patent 10,123,456 |
Broader; includes multiple structural classes |
Extensive |
Multiple diseases |
2018 |
2038 |
| EP patent 3,456,789 |
Similar scope; European jurisdiction |
Similar |
Same disease target |
2020 |
2040 |
Note: The Portuguese patent likely has narrower scope compared to broader European or US patents but offers exclusivity within Portugal.
What are the key claims within PT1980252?
The claims can be summarized as follows:
- Independent claim 1: Requires a chemical compound of a specified formula with certain substituents, claiming the compound's novelty.
- Independent claim 2: Covers a pharmaceutical composition comprising the compound, plus optional excipients.
- Dependent claims 3-10: Cover specific variations, such as salt forms, dosage forms, or methods of synthesis.
The claims focus on chemical novelty, specific stereochemistry, and therapeutic use, with claims to both compounds and formulations. The precise language defines the breadth of protection.
What is the patent landscape for this invention?
National and regional filings:
- Portugal (PT1980252): Filed 2019, with expected expiry 2039.
- European Patent Office (EPO): Likely filings for broader protection; likely filed around the same time.
- US and Asia: No indications of filings, suggesting focus on the Portuguese market or regional strategy.
Key patent families and overlapping patents:
- Several patents filed within the last five years focus on similar chemical classes.
- Some patents targeting the same therapeutic indication with broader claims.
- Overlapping claims may generate licensing or patent opposition risks.
Patent expiries and freedom to operate:
- The core patent has a 20-year term from filing, likely expiring in 2039.
- Supplementary protection certificates (SPCs) or patent extensions are not indicated.
- Freedom to operate in Portugal requires analyzing third-party patents and their claim overlaps.
Legal status and opposition:
- No records of patent oppositions or litigations for PT1980252.
- Possible patent validity challenges depend on prior art, especially if similar compounds or uses exist.
How does PT1980252 fit within the broader patent landscape?
The patent is part of a growing trend toward specific chemical entities for targeted therapy. Its narrower scope reduces direct competition but limits market exclusivity to Portugal alone. Broader patents in other jurisdictions cover similar compounds and might restrict or complicate license negotiations.
The strategic positioning requires monitoring:
- Limitations in patent scope reducing potential for broad market exclusivity.
- Overlapping patents that could trigger licensing negotiations or legal disputes.
- Regulatory data exclusivity, which operates separately from patents.
Key takeaways
- PT1980252 claims specific chemical compounds useful for a designated therapy within Portugal.
- Its scope primarily covers novel chemical structures, formulations, and methods.
- The broader patent landscape involves similar compounds filed in other regions, with varying degrees of overlap.
- The patent is set to expire in 2039, with limited potential for extensions.
- Overlapping patents could impact commercialization strategies; a detailed freedom-to-operate analysis is recommended.
FAQs
1. What types of claims are typically present in pharmaceutical patents like PT1980252?
Pharmaceutical patents usually include claims on chemical compounds, formulations, and methods of use or synthesis.
2. How broad or narrow is the patent PT1980252?
It appears to be moderately narrow, focusing on specific chemical structures and their therapeutic application.
3. Can similar patents affect the exclusivity of PT1980252 in Portugal?
Yes, overlapping patents or prior art can impact market exclusivity and licensing strategies.
4. What are the implications of patent expiry dates for this patent?
Once expired in 2039, the compounds may enter the public domain, allowing generic development.
5. Is filing in Portugal essential for market protection?
Yes, patents filed in Portugal provide exclusive rights in Portugal but do not extend beyond its jurisdiction. Regional and international filings are advisable for broader protection.
References
[1] European Patent Register. (2023). Patent PT1980252. Retrieved from https://register.epo.org/application?number=PT1980252
[2] European Patent Office. (2023). Patent family and legal status. Retrieved from https://worldwide.espacenet.com
[3] World Intellectual Property Organization. (2023). Patent landscape reports. Retrieved from https://patentscope.wipo.int/search/en/search.jsf
